98%
921
2 minutes
20
Studies involving transcriptomics have revealed multiple molecular subtypes of hepatocellular carcinoma (HCC). Positron emission tomography/computed tomography (PET/CT) has also identified distinct molecular imaging subtypes, including those with increased and decreased choline metabolism as measured by the tissue uptake of the radiopharmaceutical F-fluorocholine. Gene signatures reflecting the molecular heterogeneity of HCC may identify the biological and clinical significance of these imaging subtypes. In this study, 41 patients underwent F-fluorocholine PET/CT, followed by tumor resection and gene expression profiling. Over- and underexpressed components of previously published gene signatures were evaluated for enrichment between tumors with high and low F-fluorocholine uptake using gene set analysis. Significant gene sets were enumerated by FDR based on phenotype permutation. Associations with overall survival were analyzed by univariate and multivariate proportional hazards regression. Ten gene sets related to HCC were significantly associated with high tumor F-fluorocholine uptake at FDR < 0.05, including those from three different clinical molecular classification systems and two prognostic signatures for HCC that showed predictive value in the study cohort. Tumor avidity for F-fluorocholine was associated with favorable characteristics based on these signatures with lower mortality based on survival analysis (HR 0.36; 95% confidence interval, 0.14-0.95). Tumors demonstrating high F-fluorocholine uptake were also enriched for genes involved in oxidative phosphorylation, fatty acid metabolism, peroxisome, bile acid metabolism, xenobiotic metabolism, and adipogenesis. These results provide a pathobiological framework to further evaluate F-fluorocholine PET/CT as a molecular and prognostic classifier in HCC. SIGNIFICANCE: A pathobiological framework for HCC brings together multiple prognostically relevant gene signatures via convergence with F-fluorocholine PET/CT imaging phenotype.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6494445 | PMC |
http://dx.doi.org/10.1158/0008-5472.CAN-18-3837 | DOI Listing |
J Nucl Med Technol
September 2025
Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and the General University Hospital in Prague, Prague, Czech Republic;
The aim of the study was to validate a new method for semiautomatic subtraction of [Tc]Tc-sestamibi and [Tc]NaTcO SPECT 3-dimensional datasets using principal component analysis (PCA) against the results of parathyroid surgery and to compare its performance with an interactive method for visual comparison of images. We also sought to identify factors that affect the accuracy of lesion detection using the two methods. Scintigraphic data from [Tc]Tc-sestamibi and [Tc]NaTcO SPECT were analyzed using semiautomatic subtraction of the 2 registered datasets based on PCA applied to the region of interest including the thyroid and an interactive method for visual comparison of the 2 image datasets.
View Article and Find Full Text PDFMol Imaging Radionucl Ther
September 2025
University Clinical Center of Serbia, Center for Nuclear Medicine with PET, Belgrade, Serbia.
Fluorine-fluorocholine (F-FCH) is a radiopharmaceutical used in primary hyperparathyroidism. The data about its utility in malignancies other than prostate and hepatocellular carcinoma is limited. We present the case of a patient who was referred for F-FCH positron emission tomography/computed tomography (PET/CT) due to the persistently elevated parathormone and calcium levels following total thyroidectomy with left lower parathyroidectomy for parathyroid carcinoma (PTC).
View Article and Find Full Text PDFCancers (Basel)
August 2025
Department of Nuclear Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Background/objectives: This study aims to evaluate the additional value of [F]F-fluorocholine ([F]F-FCH) PET/CT over contrast-enhanced magnetic resonance imaging (CE-MRI) in detecting the recurrence of brain metastases (BMs) after stereotactic radiosurgery (SRS) in patients with lung cancer brain metastases (LCBMs).
Methods: Thirty-one patients with suspected recurrence of BM in LCBM after SRS were enrolled in this retrospective study. They underwent both [F]F-FCH PET/CT and CE-MRI within 2 weeks.
Surgery
August 2025
Department of Surgery, University Hospital Fundación Jiménez Díaz, Madrid, Spain.
Background: Primary hyperparathyroidism is a common endocrine disorder. Accurate preoperative localization is crucial for the success of minimally invasive parathyroidectomy. Although mTc-methoxy-isobutyl-isonitrol single photon emission computed tomography-computed tomography remains the gold standard imaging technique, its diagnostic performance can be limited in certain clinical scenarios.
View Article and Find Full Text PDFFront Endocrinol (Lausanne)
July 2025
Department of Nuclear Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Background: Currently F-Fluorocholine (FCH)-PET/CT is a choice beyond widely used techniques like ultrasound (US) and technetium-99m sestamibi (MIBI) for primary hyperparathyroidism (pHPT). It remains uncertain how FCH-PET/CT collaborates with those two traditional modalities. This study aims to prospectively evaluate the effectiveness of individual, complementary, and combined utilization of FCH-PET/CT for preoperative localization.
View Article and Find Full Text PDF